These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 37716913)

  • 1. TAZ facilitates breast tumor growth by promoting an immune-suppressive tumor microenvironment.
    Gershoni A; Hassin O; Nataraj NB; Baruch S; Avioz-Seligman A; Pirona AC; Fellus-Alyagor L; Meir Salame T; Mukherjee S; Mallel G; Yarden Y; Aylon Y; Oren M
    Mol Oncol; 2023 Dec; 17(12):2675-2693. PubMed ID: 37716913
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Loss-of-function of the hippo transducer TAZ reduces mammary tumor growth through a myeloid-derived suppressor cell-dependent mechanism.
    Shen H; Zhang Y; Kramer ED; Katsuta E; Wan Y; Chen Y; Wang J; Zhang Y; Matsuzaki J; Frangou C; Abrams SI; Zhang J
    Cancer Gene Ther; 2022 Nov; 29(11):1791-1800. PubMed ID: 35840667
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hippo-TAZ signaling is the master regulator of the onset of triple-negative basal-like breast cancers.
    Soyama H; Nishio M; Otani J; Sakuma T; Takao S; Hara S; Masuda T; Mimori K; Toyokuni S; Lydon JP; Nakao K; Nishina H; Fukumoto T; Maehama T; Suzuki A
    Proc Natl Acad Sci U S A; 2022 Jul; 119(29):e2123134119. PubMed ID: 35858357
    [TBL] [Abstract][Full Text] [Related]  

  • 4. YAP and TAZ are transcriptional co-activators of AP-1 proteins and STAT3 during breast cellular transformation.
    He L; Pratt H; Gao M; Wei F; Weng Z; Struhl K
    Elife; 2021 Aug; 10():. PubMed ID: 34463254
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Hippo Pathway Component TAZ Promotes Immune Evasion in Human Cancer through PD-L1.
    Janse van Rensburg HJ; Azad T; Ling M; Hao Y; Snetsinger B; Khanal P; Minassian LM; Graham CH; Rauh MJ; Yang X
    Cancer Res; 2018 Mar; 78(6):1457-1470. PubMed ID: 29339539
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Non-secreting pituitary tumours characterised by enhanced expression of YAP/TAZ.
    Xekouki P; Lodge EJ; Matschke J; Santambrogio A; Apps JR; Sharif A; Jacques TS; Aylwin S; Prevot V; Li R; Flitsch J; Bornstein SR; Theodoropoulou M; Andoniadou CL
    Endocr Relat Cancer; 2019 Jan; 26(1):215-225. PubMed ID: 30139767
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SKI activates the Hippo pathway via LIMD1 to inhibit cardiac fibroblast activation.
    Landry NM; Rattan SG; Filomeno KL; Meier TW; Meier SC; Foran SJ; Meier CF; Koleini N; Fandrich RR; Kardami E; Duhamel TA; Dixon IMC
    Basic Res Cardiol; 2021 Apr; 116(1):25. PubMed ID: 33847835
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non-hippo kinases: indispensable roles in YAP/TAZ signaling and implications in cancer therapy.
    Zhu J; Wu T; Lin Q
    Mol Biol Rep; 2023 May; 50(5):4565-4578. PubMed ID: 36877351
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reciprocal regulation of YAP/TAZ by the Hippo pathway and the Small GTPase pathway.
    Jang JW; Kim MK; Bae SC
    Small GTPases; 2020 Jul; 11(4):280-288. PubMed ID: 29457552
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Hippo effector TAZ (WWTR1) transforms myoblasts and TAZ abundance is associated with reduced survival in embryonal rhabdomyosarcoma.
    Mohamed A; Sun C; De Mello V; Selfe J; Missiaglia E; Shipley J; Murray GI; Zammit PS; Wackerhage H
    J Pathol; 2016 Sep; 240(1):3-14. PubMed ID: 27184927
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TAZ maintains telomere length in TNBC cells by mediating Rad51C expression.
    Yang L; Wang B; Jiao X; Zhou C; Chen S; Gao X; Sun W; Song S; Li J; Liu J; Wang Y; Liu P
    Breast Cancer Res; 2021 Sep; 23(1):89. PubMed ID: 34488828
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TAZ Protein Accumulation Is Negatively Regulated by YAP Abundance in Mammalian Cells.
    Finch-Edmondson ML; Strauss RP; Passman AM; Sudol M; Yeoh GC; Callus BA
    J Biol Chem; 2015 Nov; 290(46):27928-38. PubMed ID: 26432639
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The oncogenic roles and clinical implications of YAP/TAZ in breast cancer.
    Luo J; Zou H; Guo Y; Tong T; Chen Y; Xiao Y; Pan Y; Li P
    Br J Cancer; 2023 May; 128(9):1611-1624. PubMed ID: 36759723
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An indispensable role of TAZ in anoikis resistance promoted by OTUB1 deubiquitinating enzyme in basal-like triple-negative breast cancer cells.
    Nakagawa H; Higurashi M; Ishikawa F; Mori K; Shibanuma M
    Biochem Biophys Res Commun; 2023 Mar; 649():1-9. PubMed ID: 36738577
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The receptor tyrosine kinase EphA2 promotes glutamine metabolism in tumors by activating the transcriptional coactivators YAP and TAZ.
    Edwards DN; Ngwa VM; Wang S; Shiuan E; Brantley-Sieders DM; Kim LC; Reynolds AB; Chen J
    Sci Signal; 2017 Dec; 10(508):. PubMed ID: 29208682
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PYK2 negatively regulates the Hippo pathway in TNBC by stabilizing TAZ protein.
    Kedan A; Verma N; Saroha A; Shreberk-Shaked M; Müller AK; Nair NU; Lev S
    Cell Death Dis; 2018 Sep; 9(10):985. PubMed ID: 30250159
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cysteine S-Glutathionylation Promotes Stability and Activation of the Hippo Downstream Effector Transcriptional Co-activator with PDZ-binding Motif (TAZ).
    Gandhirajan RK; Jain M; Walla B; Johnsen M; Bartram MP; Huynh Anh M; Rinschen MM; Benzing T; Schermer B
    J Biol Chem; 2016 May; 291(22):11596-607. PubMed ID: 27048650
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hippo/YAP signaling choreographs the tumor immune microenvironment to promote triple negative breast cancer progression via TAZ/IL-34 axis.
    Wang Z; Wang F; Ding XY; Li TE; Wang HY; Gao YH; Wang WJ; Liu YF; Chen XS; Shen KW
    Cancer Lett; 2022 Feb; 527():174-190. PubMed ID: 34929335
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanosignaling through YAP and TAZ drives fibroblast activation and fibrosis.
    Liu F; Lagares D; Choi KM; Stopfer L; Marinković A; Vrbanac V; Probst CK; Hiemer SE; Sisson TH; Horowitz JC; Rosas IO; Fredenburgh LE; Feghali-Bostwick C; Varelas X; Tager AM; Tschumperlin DJ
    Am J Physiol Lung Cell Mol Physiol; 2015 Feb; 308(4):L344-57. PubMed ID: 25502501
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synaptopodin-2 suppresses metastasis of triple-negative breast cancer via inhibition of YAP/TAZ activity.
    Liu J; Ye L; Li Q; Wu X; Wang B; Ouyang Y; Yuan Z; Li J; Lin C
    J Pathol; 2018 Jan; 244(1):71-83. PubMed ID: 28991374
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.